| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S87639-5mg买3赠1 |
98.54% | ￥400.00 |
7 | - | - | - | - |
|
S87639-10mg买3赠1 |
98.54% | ￥670.00 |
3 | - | - | - | - |
|
S87639-25mg买3赠1 |
98.54% | ￥1120.00 |
8 | - | - | - | - |
|
S87639-100mg买3赠1 |
98.54% | ￥2800.00 |
6 | - | - | - | - |
|
| 产品描述： | SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | G protein-coupled Bile Acid Receptor 1;GPCR19 | ||||||||||||||||||||
| 体外研究： | SBI-115 (100-200 µM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes. Cell Proliferation Assay Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100, 200 µM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA. | ||||||||||||||||||||
| 参考文献： | 1. Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66(4):1197-1218. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京